Skip to product information
1 of 1

GeneBio Systems

Recombinant Mouse Cripto-1 Protein(Fc Tag)

Recombinant Mouse Cripto-1 Protein(Fc Tag)

SKU:PDMM100173

Regular price ¥154,400 JPY
Regular price Sale price ¥154,400 JPY
Sale Sold out
Shipping calculated at checkout.

Size:100μg

Storage:Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Shipping:This product is provided as lyophilized powder which is shipped with ice packs.

Exp date:12 months

Category ID_II:Recombinant Proteins

Category ID_III:Others

Abbreviation:Cripto-1

Target Synonym:TDGF;Cripto;Tdgf1;CRGF;teratocarcinoma-derived growth factor 1

Research Areas:

Conjugation:

Target Species:Mouse

Expression Host:Mammalian

Application:

Fusion tag:C-Fc

UNIProt ID:P51865

Accession:P51865

Background:Cripto/TDGF1 is a member of the epidermal growth factor (EGF)-Cripto, Frl-1, and Cryptic (CFC) family. EGF-CFC family member proteins share a variant EGF-like motif, a conserved cysteine-rich domain, and a C-terminal hydrophobic region. Before gastrulation, Cripto is asymmetrically expressed in a proximal–distal gradient in the epiblast, and subsequently is expressed in the primitive streak and newly formed embryonic mesoderm. These proteins play key roles in intercellular signaling pathways during vertebrate embryogenesis. Mutations in Cripto/TDGF1 can cause autosomal visceral heterotaxy. Cripto/TDGF1 is involved in left-right asymmetric morphogenesis during organ development. Cripto signalling is essential for the conversion of a proximal–distal asymmetry into an orthogonal anterior–posterior axis. The mechanism of inhibitory effects of the Cripto includes both cancer cell apoptosis, activation of c-Jun-NH(2)-terminal kinase and p38 kinase signaling pathways and blocking of Akt phosphorylation. Thus, Cripto is a unique target, and Immunohistochemistry to Cripto could be of therapeutic value for human cancers.

Concentration:

Activity:Not validated for activity

Sequence:Arg26-Gln150

Purity: > 90% as determined by reducing SDS-PAGE.

Formulation:Lyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5% Mannitol.

Reconstitution:It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis.

Endotoxin:< 1.0 EU/mg of the protein as determined by the LAL method.

Calculated MW:38.6 kDa

ObservedMW:35 kDa

View full details